PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Digestive Disease Interventions0 citations

Ablative and Existing Threshold Dosimetry for Hepatic Metastatic Disease

View Full Paper
KNKiyon Naser-TavakolianASAbin SajanRPR. Parikh

Key Points

  • The research aims to review dosimetric approaches and clinical outcomes of yttrium-90 radiation segmentectomy for hepatic metastatic disease.
  • Evaluated current evidence on dosimetric approaches for metastatic liver disease.
  • Reviewed clinical outcomes associated with radiation segmentectomy.
  • Assessed tumor-absorbed dose thresholds for radioembolization.
  • Identified established dosimetric strategies for hepatocellular carcinoma.
  • Examined less defined approaches for hepatic metastases.
  • Highlighted the importance of dose thresholds to improve treatment efficacy.

Abstract

Abstract Yttrium-90 radiation segmentectomy (RS) is well established for hepatocellular carcinoma, but less defined for hepatic metastases. This review evaluates current evidence on dosimetric approaches, clinical outcomes of RS for metastatic disease, and tumor–absorbed dose thresholds for radioembolization in metastatic liver disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Naser-Tavakolian et al. (2026) studied this question.

synapsesocial.com/papers/69d896166c1944d70ce07617https://doi.org/10.1055/a-2835-2875
Ask AI
Helpful
Bookmark
Share
View Full Paper